https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50027 Wed 28 Jun 2023 09:28:42 AEST ]]> Cannabidiol - Help and hype in targeting mucosal diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54160 Wed 28 Feb 2024 15:16:56 AEDT ]]> A systematic review of the colorectal microbiome in adult cystic fibrosis patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50302 Wed 28 Feb 2024 15:06:11 AEDT ]]> Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45110 3.5 years since last colonoscopy were 36, 93, 56 and 33, respectively. Among these, 16.7, 19.4, 9.9 and 15.1% were stage III–IV, respectively (p = 0.34). The cancers detected more than 2.5 years after the last colonoscopy were not more advanced than those diagnosed earlier (p = 0.14). Conclusions: The CRC stage and interval since last colonoscopy were not correlated, which is in conflict with the accelerated adenoma-carcinoma paradigm. We have previously reported that more frequent colonoscopy is not associated with lower incidence of CRC in path_MMR carriers as was expected. In contrast, point estimates showed a higher incidence with shorter intervals between examinations, a situation that may parallel to over-diagnosis in breast cancer screening. Our findings raise the possibility that some CRCs in path_MMR carriers may spontaneously disappear: the host immune response may not only remove CRC precursor lesions in path_MMR carriers, but may remove infiltrating cancers as well. If confirmed, our suggested interpretation will have a bearing on surveillance policy for path_MMR carriers.]]> Wed 26 Oct 2022 14:12:41 AEDT ]]> Elastin is a key factor of tumor development in colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45076 ELN gene expression in tumors from CRC patients and adjacent non-tumor colon tissues and healthy controls from two existing microarray datasets. ELN protein was measured in human normal colon cells and colon cancer epithelial cells and tumor development was assessed in colon epithelial cells cultured in medium with or without ELN peptide on plates coated with ELN recombinant protein. Control plates were coated with PBS only. Results: We found ELN gene expression was increased in tumors from CRC patients compared to adjacent non-tumor tissues and healthy controls. ELN protein was increased in cancer cells compared to normal colon epithelial cells. Transforming growth factor beta (TGF-β) was a key cytokine to induce production of ECM proteins, but it did not induce ELN expression in colon cancer cells. Matrix metalloproteinase 9 (MMP9) gene expression was increased, but that of MMP12 (elastase) did not change between CRC patients and control. Tissue inhibitor of metalloproteinases 3 (TIMP3) gene expression was decreased in colon tissues from CRC patients compared to healthy controls. However, MMP9, MMP12 and TIMP3 proteins were increased in colon cancer cells. ELN recombinant protein increased proliferation and wound healing in colon cancer epithelial cells. This had further increased in cancer cells incubated in plates coated with recombinant ELN coated plate and in culture media containing ELN peptide. A potential mechanism was that ELN induced epithelial mesenchymal transition with increased alpha-smooth muscle actin and vimentin proteins but decreased E-cadherin protein. Tumor necrosis factor alpha (TNF) mRNA was also increased in CRC patients compared to controls. ELN recombinant protein induced further increases in TNF protein in mouse bone marrow derived macrophages after lipopolysaccharide stimulation. Conclusions: These data suggest ELN regulates tumor development and the microenvironment in CRC.]]> Wed 26 Oct 2022 12:30:48 AEDT ]]> Targeted sequencing of genes associated with the mismatch repair pathway in patients with endometrial cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45052 MLH1, MSH2, MSH6 and PMS2 cause Lynch syndrome that implies an increased cancer risk, where colon and endometrial cancer are the most frequent. Identification of these pathogenic variants is important to identify endometrial cancer patients with inherited increased risk of new cancers, in order to offer them lifesaving surveillance. However, several other genes are also part of the MMR pathway. It is therefore relevant to search for variants in additional genes that may be associated with cancer risk by including all known genes involved in the MMR pathway. Next-generation sequencing was used to screen 22 genes involved in the MMR pathway in constitutional DNA extracted from full blood from 199 unselected endometrial cancer patients. Bioinformatic pipelines were developed for identification and functional annotation of variants, using several different software tools and custom programs. This facilitated identification of 22 exonic, 4 UTR and 9 intronic variants that could be classified according to pathogenicity. This study has identified several germline variants in genes of the MMR pathway that potentially may be associated with an increased risk for cancer, in particular endometrial cancer, and therefore are relevant for further investigation. We have also developed bioinformatics strategies to analyse targeted sequencing data, including low quality data and genomic regions outside of the protein coding exons of the relevant genes.]]> Wed 26 Oct 2022 11:45:52 AEDT ]]> Testing the effectiveness of a general practice intervention to improve uptake of colorectal cancer screening: a randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36863 Wed 24 May 2023 12:15:34 AEST ]]> 8q23.3 and 11q23.1 as modifying loci influencing the risk for CRC in Lynch syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23155 Wed 24 Aug 2016 15:58:37 AEST ]]> Prevalence of appropriate colorectal cancer screening and preferences for receiving screening advice among people attending outpatient clinics https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33155 Wed 23 Feb 2022 16:01:41 AEDT ]]> Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30968 Wed 19 Jan 2022 15:15:50 AEDT ]]> The "unnatural" history of colorectal cancer in Lynch syndrome: lessons from colonoscopy surveillance https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42759 Wed 19 Apr 2023 09:40:07 AEST ]]> Colorectal cancer metastatic disease progression in Australia: a population-based analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34273 79 years vs < 60 years: 1.38 for colon, 1.69 for rectal cancer). Risk of disease progression was significantly lower for females, and varied by histology type. For colon cancer, the risk of disease progression decreased over time. For rectal cancer, risk of metastatic progression was significantly higher for those living in more socioeconomically disadvantaged areas compared with those in the least disadvantaged area. Conclusions: An understanding of the variation in risk of metastatic progression is useful for planning health service requirements, and can help inform decisions about treatment and follow-up for colorectal cancer patients.]]> Wed 17 Nov 2021 16:32:24 AEDT ]]> Colorectal carcinoma in the course of inflammatory bowel diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36834 Wed 17 Nov 2021 16:29:24 AEDT ]]> Costs and cost-effectiveness of targeted, personalized risk information to increase appropriate screening by first-degree relatives of people with colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36186 Wed 17 Nov 2021 16:28:40 AEDT ]]> Identification of new causative genes in inherited colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37271 Wed 16 Sep 2020 13:54:41 AEST ]]> Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31511 Wed 15 Dec 2021 16:09:40 AEDT ]]> Socioeconomic disparities in colorectal cancer survival: contributions of prognostic factors in a large Australian cohort https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44295 Wed 13 Mar 2024 08:55:55 AEDT ]]> Factors associated with consultation behaviour for primary symptoms potentially indicating colorectal cancer: a cross-sectional study on response to symptoms https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14299 Wed 11 Apr 2018 17:07:41 AEST ]]> Colorectal cancer screening in Australia: a community-level perspective https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22259 Wed 11 Apr 2018 16:19:15 AEST ]]> Improving adherence to surveillance and screening recommendations for people with colorectal cancer and their first degree relatives: A randomized controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14000 Wed 11 Apr 2018 15:52:05 AEST ]]> Folate status, folate-related genes and serum miR-21 expression: implications for miR-21 as a biomarker https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26544 Wed 11 Apr 2018 15:40:57 AEST ]]> Using administrative health data to describe colorectal and lung cancer care in New South Wales, Australia: a validation study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15194 Wed 11 Apr 2018 15:37:49 AEST ]]> Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17045 Wed 11 Apr 2018 14:36:26 AEST ]]> Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17052 2=0.38, P<0.0006), whereas mucositis was predicted by age, TL and PLR (R²=0.34, P<0.001). For the weekly schedule diarrhoea predominated (16%), with female gender as the only predictive factor. Although measures of uracil metabolism correlated well with 5FU metabolism (r=0.45–0.49), they did not indicate abnormal pyrimidine metabolism in this cohort and not surprisingly failed to predict for 5FU toxicity. Conclusion: Short TL of PBMNC and an increased PLR were strong predictors of mucositis and haematological toxicity in CRC patients undergoing 5FU treatment in the adjuvant setting.]]> Wed 11 Apr 2018 14:25:46 AEST ]]> Methylation diet and methyl group genetics in risk for adenomatous polyp occurrence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28251 Wed 11 Apr 2018 14:22:59 AEST ]]> Colorectal cancer risk assessment and screening recommendation: a community survey of healthcare providers' practice from a patient perspective https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14317 Wed 11 Apr 2018 14:17:15 AEST ]]> Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15053 Wed 11 Apr 2018 13:24:44 AEST ]]> Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10390 Wed 11 Apr 2018 12:49:05 AEST ]]> Copy number variants and their role in hereditary breast cancer and hereditary colorectal cancers https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22038 Wed 11 Apr 2018 12:26:23 AEST ]]> Community approaches to increasing colorectal screening uptake: a review of the methodological quality and strength of evidence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13995 Wed 11 Apr 2018 11:26:24 AEST ]]> MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17258 Wed 11 Apr 2018 11:05:43 AEST ]]> Mechanisms of epigenetic regulation of gene expression in colorectal cancer cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11905 Wed 11 Apr 2018 10:56:58 AEST ]]> Genetic variants in MUTYH are not associated with endometrial cancer risk https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6851 Wed 11 Apr 2018 10:50:17 AEST ]]> A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14003 Wed 11 Apr 2018 10:28:54 AEST ]]> 5-Fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-d https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18028 Wed 11 Apr 2018 09:44:48 AEST ]]> Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13894 Wed 11 Apr 2018 09:40:23 AEST ]]> Can a print-based intervention increase screening for first degree relatives of people with colorectal cancer? A randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27571 Wed 10 Nov 2021 15:12:50 AEDT ]]> Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24821 Wed 09 Feb 2022 15:56:19 AEDT ]]> New EPCAM founder deletion in Polish population https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34658 A in MLH1 gene and c.942+3A > T in MSH2, the deletion mutation encompassing EPCAM is one of the most common causative changes responsible for LS in Poland.]]> Wed 09 Feb 2022 15:54:51 AEDT ]]> Finding needles in haystacks: the use of quantitative proteomics for the early detection of colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46915 Wed 07 Dec 2022 09:37:40 AEDT ]]> Use of multigene-panel identifies pathogenic variants in several CRC-predisposing genes in patients previously tested for Lynch Syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34524 Wed 06 Apr 2022 13:58:28 AEST ]]> Comparison of colonic neoplasia detection rates in patients screened inside and outside the national bowel cancer screening program https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38855 Tue 22 Feb 2022 15:26:26 AEDT ]]> Targeted next-generation sequencing of 22 mismatch repair genes identifies Lynch syndrome families https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30018 Tue 20 Sep 2022 14:49:52 AEST ]]> Evaluation of a Multi-Gene Methylation Blood-Test for the Detection of Colorectal Cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54341 Tue 20 Feb 2024 16:12:28 AEDT ]]> Identification of nine new susceptibility loci for endometrial cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47028 Tue 13 Dec 2022 15:55:21 AEDT ]]> Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51614 Tue 12 Sep 2023 13:49:19 AEST ]]> A qualitative evaluation of the STOMA psychosocial intervention programme for colorectal cancer patients with stoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34934 Thu 28 Oct 2021 12:36:04 AEDT ]]> Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45013 Thu 27 Oct 2022 17:46:24 AEDT ]]> Microbiome and Metabolic Features of Tissues and Feces Reveal Diagnostic Biomarkers For Colorectal Cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50515 Thu 27 Jul 2023 14:34:40 AEST ]]> KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28574 Thu 27 Jan 2022 15:55:35 AEDT ]]> The future colorectal cancer burden attributable to modifiable behaviors: a pooled cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35110 Pdifference < .001). The burden attributed to these factors was also higher for those born in Australia (28.7%) than elsewhere (16.8%, Pdifference = .047). We observed modification of the smoking-attributable burden by alcohol consumption and educational attainment, and modification of the obesity-attributable burden by age group and birthplace. Conclusions: We produced up-to-date estimates of the future CRC burden attributed to modifiable behaviors. We revealed novel differences between men and women, and other high–CRC burden subgroups that could potentially benefit most from programs that support behavioral change and early detection.]]> Thu 24 Mar 2022 11:32:50 AEDT ]]> Integrin αvβ6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19627 Thu 23 Aug 2018 11:24:40 AEST ]]> Critical issues on diverticular disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39916 Thu 21 Jul 2022 10:02:24 AEST ]]> Exome sequencing of familial adenomatous polyposis-like individuals identifies both known and novel causative genes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48845 Thu 20 Apr 2023 10:58:52 AEST ]]> Testing the effectiveness of a primary care intervention to improve uptake of colorectal cancer screening: a randomized controlled trial protocol https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33156 Thu 17 Mar 2022 14:34:24 AEDT ]]> Pilot trial of a STOMA psychosocial intervention programme for colorectal cancer patients with stomas https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36206 Thu 17 Feb 2022 09:29:46 AEDT ]]> Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39890 Thu 14 Jul 2022 14:21:17 AEST ]]> Identifying incident colorectal and lung cancer cases in health service utilisation databases in Australia: a validation study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30828 50% or PPV >65% for either cancer type and no combination of indicators increased both the sensitivity and PPV above that achieved using the hospital cancer diagnosis data. All specificities were close to 100%; 95% confidence intervals for sensitivity and PPV were generally +/−2%. Conclusions: In NSW, identifying new cases of colorectal and lung cancer from administrative health datasets, such as hospital records, is a feasible alternative when cancer registry data are not available. However, the strengths and limitations of the different data sources should be borne in mind.]]> Thu 13 Jan 2022 10:30:22 AEDT ]]> Experiences of colorectal cancer patients in the 2-years post-diagnosis and patient factors predicting poor outcome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27926 Thu 09 Dec 2021 11:02:56 AEDT ]]> INPP4B is an oncogenic regulator in human colon cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29220 Thu 08 Aug 2024 13:08:51 AEST ]]> Are Australian general practice patients appropriately screened for colorectal cancer? A cross-sectional study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31500 Thu 04 Nov 2021 10:39:18 AEDT ]]> Automatic colonic polyp detection by the mapping using regional unit sphere https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7770 = 10mm in diameter were detected, 90% of polyps >= 6mm in diameter were detected and 70% of polyps < 6mm in diameter were detected at 7.0 FPs per patient.]]> Sat 24 Mar 2018 08:41:56 AEDT ]]> Clinical characteristics of tumors derived from colorectal cancer patients who harbor the Tumor Necrosis Factor beta-1031T/T and NOD2 3020insC polymorphism https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8123 Sat 24 Mar 2018 08:40:02 AEDT ]]> MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8339 T and 1298 A>C, that alter the function of the encoded protein have been the focus of many studies on CRC risk outside the context of an inherited predisposition to disease. In this report, a total of 417 HNPCC participants were genotyped for the 677 C>T and 1298 A>C SNPs to determine whether there exists an association with the age of disease onset of CRC. Genotyping of both SNPs was performed by TaqMan assay technology. Associations in disease risk were further investigated using Kaplan–Meier survival analysis and Cox hazard regression. The average ages of disease diagnosis were found to be different between individuals harbouring either one of the MTHFR polymorphisms. Both Kaplan–Meier and Cox hazard regression analyses revealed a more complex relationship between the two polymorphisms and the age of CRC onset. The Kaplan–Meier survival analysis revealed that compound heterozygotes for the two SNPs developed CRC 10 years later compared with those carrying only wild-type alleles.]]> Sat 24 Mar 2018 08:39:40 AEDT ]]> Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7033 Sat 24 Mar 2018 08:37:51 AEDT ]]> Reducing inequities in cancer care: the role of cancer registries https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7119 Sat 24 Mar 2018 08:34:11 AEDT ]]> Norcantharidin induces HT-29 colon cancer cell apoptosis through the αvβ6-extracellular signal-related kinase signaling pathway https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7110 Sat 24 Mar 2018 08:34:09 AEDT ]]> Colorectal cancer screening: ensuring benefits outweigh the risks (editorial) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7248 Sat 24 Mar 2018 08:33:51 AEDT ]]> Can a tailored telephone intervention delivered by volunteers reduce the supportive care needs, anxiety and depression of people with colorectal cancer? A randomized controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14137 Sat 24 Mar 2018 08:24:52 AEDT ]]> Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13923 Sat 24 Mar 2018 08:24:50 AEDT ]]> Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12304 50 values between 0.23 and 7.6 μM. Addition of pyridoxine at concentrations of 1–25 μM does not affect OHP cytotoxicity. Conclusions: Administration of pyridoxine, at concentrations extending across possible therapeutic plasma levels in humans, does not antagonise OHP antitumour effects in a range of relevant tumour cell lines. This study provides a foundation for clinical studies to test whether pyridoxine can minimise OHP-related neurotoxicity, and clinicians can be confident that pyridoxine is very unlikely to reverse the antitumour effects of OHP, as seems to be the case with Ca/Mg infusions. This could prove to be a cost-effective way to minimise OHP-related neurotoxicity, allowing more effective less toxic treatment and better outcomes in patients.]]> Sat 24 Mar 2018 08:11:35 AEDT ]]> Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19006 50 of 11.4 μM (two orders of magnitude more potent than naproxen). Selectivity of 3a was investigated against a panel of three tumor and one normal colon cell lines and showed up to six times less toxicity against normal colonocytes. Compound 3a was shown to induce dose-dependent apoptosis of HT116 colon tumor cells as evidenced by measuring the activity of caspases-3 and 7. None of the synthesized compounds showed activity against COX-1 or COX-2 isozymes, confirming a COX-independent mechanism of action. Compound 3k was found to have no ulcerogenic effect in rats as indicated by electron microscope scanning of the stomach after oral administration. A pharmacophore model was developed for elucidating structure–activity relationships and subsequent chemical optimization for this series of compounds as colorectal cancer chemopreventive drugs.]]> Sat 24 Mar 2018 08:05:35 AEDT ]]> Cell cycle-related genes as modifiers of age of onset of colorectal cancer in Lynch syndrome: a large-scale study in non-Hispanic white patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19920 Sat 24 Mar 2018 08:03:46 AEDT ]]> Methoxyphenylcipro induces antitumor activity in human cancer cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17312 Sat 24 Mar 2018 08:01:52 AEDT ]]> Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19967 Sat 24 Mar 2018 07:58:34 AEDT ]]> Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19618 Sat 24 Mar 2018 07:58:24 AEDT ]]> Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21235 N = 28 854) and CC-free (N = 86 562) patients had mean age 61.9 years; 66.7% were female. One-year CRCancer prevalence was 2.7% and 1.7%, and BCN prevalence was 24.8% and 11.9% for CC and CC-free patients, respectively. Adjusted IRRs between CC and CC-free patients were 1.59 [95% confidence interval (CI): 1.43-1.78] and 2.60 [95% CI: 1.51-2.70] for CRCancer and BCN, respectively. Patients with severe and very severe CC had significantly greater incidence of CRCancer and BCN. At ≥2 and ≥5 years of observation, CRCancer and BCN incidence remained consistently and significantly higher for CC patients. Conclusions Patients with chronic constipation are associated with significantly higher prevalence and incidence of colorectal cancer and benign colorectal neoplasm than matched chronic constipation-free patients. These risks increase with the severity of chronic constipation.]]> Sat 24 Mar 2018 07:53:01 AEDT ]]> Colonoscopy findings in high-risk individuals compared to an average-risk control population https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28377 Sat 24 Mar 2018 07:36:05 AEDT ]]> Altholactone induces apoptotic cell death in human colorectal cancer cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28516 Sat 24 Mar 2018 07:29:20 AEDT ]]> Comparing colorectal cancer treatment and survival for Aboriginal and non-Aboriginal people in New South Wales https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25922 Sat 24 Mar 2018 07:27:50 AEDT ]]> Cumulative effects of genetic markers and the detection of advanced colorectal neoplasias by population screening https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26445 Sat 24 Mar 2018 07:27:17 AEDT ]]> Genetic variation in glutamate carboxypeptidase II and interaction with dietary natural vitamin C may predict risk for adenomatous polyp occurrence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28911 Sat 24 Mar 2018 07:26:00 AEDT ]]> Physical and psychological predictors of quality of life in Chinese colorectal cancer patients during chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26751 Sat 24 Mar 2018 07:24:43 AEDT ]]> Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4898 Sat 24 Mar 2018 07:22:58 AEDT ]]> Prevalence of FOB testing in eastern-Australian general practice patients: What has a national bowel cancer screening program delivered? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24291 Sat 24 Mar 2018 07:14:41 AEDT ]]> A randomized controlled trial examining the effectiveness of a STOMA psychosocial intervention programme on the outcomes of colorectal patients with a stoma: study protocol https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24694 Sat 24 Mar 2018 07:10:54 AEDT ]]> Metformin: a salutary candidate for colorectal cancer treatment in patients with diabetes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46664 Mon 28 Nov 2022 18:32:29 AEDT ]]> MTHFR C677T and A1298C polymorphism’s effect on risk of colorectal cancer in Lynch syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53956 Mon 22 Jan 2024 17:02:37 AEDT ]]> Amino alcohol acrylonitriles as broad spectrum and tumour selective cytotoxic agents https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40209 Mon 08 Aug 2022 13:40:19 AEST ]]> The Prognostic Utility of KRAS Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54935 Fri 22 Mar 2024 14:31:53 AEDT ]]> Current opinion on optimal treatment for colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20065 Fri 21 Aug 2015 13:38:26 AEST ]]> Inhibition of HSP90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28221 Fri 16 Oct 2020 16:09:46 AEDT ]]> Strategies to improve adherence to colorectal cancer screening https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35607 Fri 13 Sep 2019 16:23:20 AEST ]]> Assessment of family history of colorectal cancer in primary care: perceptions of first degree relatives of people with colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13846 Fri 10 Mar 2023 19:20:41 AEDT ]]> Have we increased our efforts to identify strategies which encourage colorectal cancer screening in primary care patients? A review of research outputs over time https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33003 Fri 10 Mar 2023 19:15:55 AEDT ]]> A randomized controlled trial of the effectiveness of a pre-recruitment primer letter to increase participation in a study of colorectal screening and surveillance. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14091 Fri 10 Mar 2023 19:12:48 AEDT ]]> Can models of self-management support be adapted across cancer types? A comparison of unmet self-management needs for patients with breast or colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30002 Fri 10 Mar 2023 19:02:11 AEDT ]]> Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44106 Fri 07 Oct 2022 13:58:36 AEDT ]]> Low blood-as levels and selected genotypes appears to be promising biomarkers for occurrence of colorectal cancer in women https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49791 Fri 02 Jun 2023 17:14:07 AEST ]]> MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49830 Fri 02 Jun 2023 16:10:29 AEST ]]>